Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics reported 2025 results and highlighted progress on its lead drug abdakibart (AVTX-009). The company expects topline data from its Phase 2 LOTUS trial in hidradenitis suppurativa in the second quarter of 2026, a key milestone for its IL‑1β-based strategy.
Cash, cash equivalents and short-term investments were $98.3 million as of December 31, 2025, which Avalo expects will fund operations into 2028. Research and development expenses rose to $50.1 million and general and administrative expenses to $22.9 million, contributing to a net loss of $78.3 million for 2025.
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle exercised stock options and sold shares in a linked set of transactions. On March 16, 2026, she exercised options to acquire 19,500 shares of common stock at $12.65 per share and 5,992 shares at $8.04 per share.
The same day, she sold 25,492 shares of common stock in open-market transactions at an average price of about $16.1465 per share, in multiple trades between $16.00 and $16.34. Following these transactions, she directly holds 3,622 common shares.
FMR LLC reports beneficial ownership of 2,125,819 shares (11.5%) of Avalo Therapeutics Inc common stock as of 02/27/2026. The filing states FMR LLC has sole voting and dispositive power over those shares and names Abigail P. Johnson with sole dispositive power; signatures reference powers of attorney and an Exhibit 99 13d-1(k)(1) agreement.
Avalo Therapeutics, Inc. reported that Chief Legal Officer Paul Varki received a grant of stock options covering 80,000 shares on February 26, 2026. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
According to the vesting terms, 25% of the option grant will vest on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years. Vesting is conditioned on Varki's continued service with the company on each applicable vesting date.
Avalo Therapeutics reported that Chief Strategy Officer Jennifer Riley received a grant of stock options giving her the right to buy 95,000 shares of common stock. The award was reported at a price of $0.00 per share, reflecting a compensatory option grant rather than an open-market trade.
According to the disclosure, the option vests 25% on February 26, 2027, with the remaining shares vesting in equal monthly installments over the following three years, as long as she continues in service on each vesting date. This filing shows an increase in her derivative equity holdings through a grant/award acquisition, not a sale of existing shares.
Avalo Therapeutics, Inc. disclosed that Chief Medical Officer Mittie Doyle received a grant of stock options for 105,000 shares on February 26, 2026. The option has an exercise price reported as $0.0000 per share. Twenty‑five percent vests on February 26, 2027, with the remaining options vesting in equal monthly installments over the following three years, conditioned on continued service.
Boyd Taylor reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics, Inc. reported that its Chief Business Officer, Boyd Taylor, received a grant of stock options covering 95,000 shares. The options were awarded as a derivative security and are held directly.
The award vests 25% on February 26, 2027, with the remaining options vesting in equal monthly installments over the following three years, subject to Boyd Taylor’s continued service on each vesting date.
Sullivan Christopher Ryan reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics reported that its Chief Financial Officer, Christopher Ryan Sullivan, received a grant of stock options representing 105,000 shares of common stock. These options were awarded on February 26, 2026 as an equity-based compensation grant.
The stock option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, conditioned on his continued service. After this grant, Sullivan held 105,000 stock options directly.
NEIL GARRY ARTHUR reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics, Inc. reported that Chief Executive Officer Neil Garry Arthur received a grant of stock options covering 286,000 shares on February 26, 2026. The option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, subject to his continued service.